Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

BMG LABTECH

BMG LABTECH is a manufacturer of a wide range of dedicated and multi-mode microplate instruments ranging from single-... read more Featured Products: More products

Download Mobile App




Rapid Method Detects Creutzfeldt-Jakob Disease in Cerebrospinal Fluid

By LabMedica International staff writers
Posted on 05 May 2015
A long-standing problem in dealing with various neurodegenerative protein misfolding diseases is early and accurate diagnosis and this is particularly important with human prion diseases.

Real-time quaking-induced conversion (RT-QuIC) assays of cerebrospinal fluid (CSF) and nasal-brushing specimens are valuable in distinguishing Creutzfeldt-Jakob Disease (CJD) from non-CJD conditions but require more than two days and up to five days to complete. More...


Scientists at the National Institutes of Health, (NIH; Hamilton, Montana, USA) and their colleagues obtained cerebrospinal fluid samples from patients with possible or probable Creutzfeldt-Jakob disease at the time of sampling, as well as from the patients with other neurologic disorders, including Alzheimer’s disease, amyotrophic lateral sclerosis, atypical Parkinsonism, dementia, dystonia, and seven other neurologic disorders.

RT-QuIC assays were performed on the CSF samples. Reaction mixtures was loaded into a black 96-well plate with a clear bottom and reaction mixtures were seeded with CSF for a final reaction volume of 100 µL. Plates were sealed and incubated in a BMG FLUOstar Omega plate reader (BMG LABTECH; Ortenberg, Germany; www.bmglabtech.com) at either 42 °C or 55 °C for 55 to 90 hours with cycles of 60 seconds of shaking and 60 seconds of rest throughout the incubation. Thioflavin T fluorescence measurements, excitation, 450 ± 10 nm; emission, 480 ± 10 nm, were taken every 45 minutes.

The improved RT-QuIC assay identified positive CSF samples within four to 14 hours with better analytical sensitivity. Moreover, analysis of 11 CJD patients demonstrated that while seven were RT-QuIC positive using the previous conditions, 10 were positive using the new assay. In these and further analyses, a total of 46 of 48 CSF samples from sporadic CJD patients were positive, while all 39 non-CJD patients were negative, giving 95.8% diagnostic sensitivity and 100% specificity.

The authors concluded that they had markedly improved RT-QuIC analysis of human CSF such that CJD and non-CJD patients can be discriminated in a matter of hours rather than days with enhanced sensitivity. These improvements should allow for much faster, more accurate, and practical testing for CJD. In broader terms, the study provides a prototype for tests for misfolded protein aggregates that cause many important amyloid diseases, such as Alzheimer’s, Parkinson’s, and tauopathies. The study was originally published on January 20, 2015, in the journal mBio.

Related Links:

US National Institutes of Health
BMG LABTECH




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.